Beam Therapeutics Inc (BEAM)

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration

BEAM-304 Development Approach Has Potential to Create Transformative, One-time Therapies for the Majority of...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference

CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology...

Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference

CAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology...

Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026

CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

Recent BEAM-302 Topline Data in Alpha-1 Antitrypsin Deficiency (AATD) Demonstrate Strong Single-dose Safety and...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements